Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
Titel:
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
Auteur:
Samalin, Emmanuelle Fouchardière, Christelle de la Thézenas, Simon Boige, Valérie Senellart, Hélène Guimbaud, Rosine Taïeb, Julien François, Eric Galais, Marie-Pierre Lièvre, Astrid Seitz, Jean-François Metges, Jean-Philippe Bouché, Olivier Boissière-Michot, Florence Lopez-Crapez, Evelyne Bibeau, Frédéric Ho-Pun-Cheung, Alexandre Ychou, Marc Adenis, Antoine Di Fiore, Frédéric Mazard, Thibault